Safety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in Stroke "ARTSS-IA"


Phase 2 Results N/A

Summary of Purpose

Background: Our prior work with combination argatroban + recombinant tissue plasminogen activator (rt-PA) (ARTSS-1: Phase IIa low-dose safety study; n=65 and ARTSS-2: Phase IIb randomized low and high-dose study; n=90), demonstrated safety of the two drugs when delivered concomitantly and recanalization rates were greater than with historical controls. Further, interim analysis of neurological outcomes at...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 20 June 2017.

1 May 2015 11 May 2015 1 Aug 2016 1 Aug 2016 1 Jun 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Masking: Open Label
  • Purpose: Treatment
  • Endpoint: Safety Study
  • Intervention: Single Group Assignment